Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- Ludwig Maximilian University of Munich
- Otto von Guericke University Magdeburg
- University Hospital Schleswig-Holstein Campus Kiel
- Goethe University Frankfurt a.M.
- University of Würzburg
- University Hospital Hamburg Eppendorf
- Kiel University
- Clinic and Polyclinic for Pediatrics and Adolescent Medicine
- Jena University Hospital
- International Epidemiology Institute
- Martin Luther University Halle-Wittenberg
- University of Cologne
- University Hospital of Würzburg
- Charité – Universitätsmedizin Berlin
Abstract
PURPOSE: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free.
METHODS: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan-Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free.
RESULTS: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49-59 years compared to < 49 years (aHR 0.70, 95% CI 0.56-0.87), female sex (aHR 0.78, 95% CI 0.65-0.93), lower educational level (aHR 0.77, 95% CI 0.64-0.93), living with a partner (aHR 0.81, 95% CI 0.66-0.99), low resilience (aHR 0.65, 95% CI 0.47-0.90), steroid treatment (aHR 0.22, 95% CI 0.05-0.90) and no medication (aHR 0.74, 95% CI 0.62-0.89) during acute infection.
CONCLUSION: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant's characteristics that are difficult to modify.
Details
Original language | English |
---|---|
Pages (from-to) | 1679-1694 |
Number of pages | 16 |
Journal | Infection |
Volume | 51 |
Issue number | 6 |
Early online date | 25 May 2023 |
Publication status | Published - Dec 2023 |
Peer-reviewed | Yes |
Externally published | Yes |
External IDs
PubMedCentral | PMC10212223 |
---|---|
Scopus | 85160410082 |
Keywords
Keywords
- Adult, COVID-19/diagnosis, Female, Humans, Middle Aged, Prospective Studies, Retrospective Studies, Risk Factors, SARS-CoV-2